OBN Adds World Class Pharma and VC Figures to its Thematic Advisory Panels

Informations

• Publié par: obn
• Nombre de lectures: 16
• Langue: English

Extrait

OBN Adds World Class Pharma and VC Figures

to its Thematic Advisory Panels

PR Newswire

OXFORD, England, June 26, 2012

OXFORD, England

,

June 26, 2012

/PRNewswire/ --

OBN, the not-for-profit business network which provides comprehensive

support for bioscience businesses in the 'Golden Triangle' biocluster and

beyond, is pleased to announce that it has established two new high level

Advisory Panels. The two Boards draw on leading experts from across the

industry and have been created in order to maintain OBN's leadership position

in program development at BioTrinity,

Europe's

3rd Largest Annual Partnering

and Investment Conference.

The Business Development and Licensing (BD&L) Advisory Panel contains

participants from big pharma through to small biotech BD&L executives,

including Amgen, Astellas Pharma Europe, Biogen Idec, Bristol-Myers Squibb,

Crescendo Biologics, Kymab, Polytherics, Prosidion, Shire and Takeda

Pharmaceuticals Europe.

Dr Jon Rees, CEO of OBN, said:

"Only by listening to key industry executives

embedded in the deal-making and licensing environment can we respond to the

needs and interests of the members in our network and continue to deliver

cutting edge content to the participants at our networking events and

conferences."

The Investor Advisory Panel draws on BioTrinity's long-standing role of bringing

a wide range of international investors together with R&D companies. It

includes participants from the UK,

Europe

and the US and from traditional

venture capital and the corporate venturing worlds. Members include 3i plc,

Abbott Biotech Ventures, Apposite Capital LLP, Boehringer Ingelheim Venture

Fund GmbH, Credit Agricole Private Equity (CAPE), Edmond de Rothschild

Investment Partners, Index Ventures, MedImmune Ventures, Merck Serono

Ventures, Sofinnova Partners, SR One (GSK), and Takeda Ventures.

Already the panel participants have given their first round of feedback and

suggestions for next year's BioTrinity panels and this will be developed to

release the preliminary BioTrinity 2013 program in

December 2012

. Combined

with OBN's recent 'Life Sciences, New Money' series of networking events and

breakfasts in

London

,

Cambridge

and

Oxford

, the advanced program

development for BioTrinity 2013 maintains OBN's leadership position in

providing comprehensive support for the UK bioindustry.

Dr Jon Rees, CEO of OBN, said:

"I am delighted with the levels of energy and

commitment the investment community, our 200 members, the wider industry

and my team are feeding into ensuring our offer continues to be more relevant

and more exciting than ever. This synergy will benefit us all."

About OBN

OBN is a not-for-profit business network which provides comprehensive support

for its member biotech and medtech companies in the

Oxford

and

South-East

England

biocluster and the rest of the UK. Our activities can be summarised as

networking, partnering, group purchasing, and fundraising advice. Through its

delivery of

Europe's

fastest growing biopartnering and investment conference,

BioTrinity, OBN generates more R&D-company-to-investor interactions than

anyone else in

Europe

. OBN is sponsored by Shire, as Corporate Patron, and

Corporate Sponsors MEPC, Manches LLP, James Cowper, George James, Ernst &

Young, Interea International, SRG, FOCUS Insurance, Ardington Archives, World

Courier and Citigate Dewe Rogerson as well as by its extensive membership of

R&D companies and other companies across the entire life sciences industry

ecosystem. OBN counts more than 200 companies amongst its membership,

which is growing over 40% per year.

For further information on OBN and its activities, please visit:

http://www.obn.org.uk

About the Advisory Panels

The two Advisory Panels contain representatives from the following companies:

Investors

Credit Agricole Private Equity (CAPE), GlaxoSmithKline, Edmond de Rothschild

Investment Partners (EdRIP), MedImmune Ventures, 3i plc, Apposite Capital

LLP, Index Ventures, Boehringer Ingelheim Venture Fund GmbH, Sofinnova

Partners, Merck Serono Ventures, Abbott Biotech Ventures, SR One

(GlaxoSmithKline), GlaxoSmithKline, Takeda Ventures.

Business Development and Licensing

Amgen, Astellas Pharma Europe, Biogen Idec, Bristol-Myers Squibb, Crescendo

Biologics, Kymab, Prosidion , Shire, Takeda Pharmaceuticals Europe,

Polytherics.

Contacts

OBN

Andy Smith, Director of Investor Relations and PR

Tel: [phone]

[e-mail]

Citigate Dewe Rogerson

Chris Gardner/Nina Enegren

T: [phone]

[e-mail] / [e-mail]